Head and neck cancer, including oral cancer, cancer of the larynx, and cancer of the pharynx, is the sixth most common type of cancer, with approximately 643,000 worldwide cases reported annually.
About 40% of tumors diagnosed in the head and neck area are diagnosed as squamous-cell carcinoma. The five year survival rate for these kinds of oral cancer ranges from 81% (patients with localized disease), 42% (with regional disease), and 17% (patients with metastasis. This rate has remained very high and relatively constant in recent decades.
The treatment of oral cancer often produces major changes in speech, chewing, swallowing and oral health, which in addition to the disease per se, affects the social life and self-esteem of the affected person.
Unlike other areas of dentistry, where new methods allow early diagnosis of many diseases, the oral examination has not changed much in the last decades. However, there seems to be a new star rising.
Introducing the VELscope Vx Enhanced Oral Assessment System, which centers on a wireless, handheld scope that uses natural tissue fluorescence to enhance the way clinicians visualize oral mucosal abnormalities that might not be apparent or even visible to the naked eye.
Recognized by the World Health Organization, the award-winning VELscope Vx is the world's most widely used adjunctive device for the enhanced visualization of oral mucosal abnormalities, such as oral cancer or pre-malignant dysplasia.
More than 25 million VELscope Vx examinations have been performed by over 15,000 dental practitioners in 23 countries. The technology is also backed by more clinical studies than any other adjunctive device for tissue fluorescence visualization.